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Abstract
Total anomalous pulmonary venous return (TAPVR) is a rare congen-
ital cardiac defect, accounting for 1.5-3% of cases of congenital heart 
disease. With prenatal ultrasonography, the majority of these patients 
are diagnosed in utero with definitive surgery performed during the 
neonatal period. However, as prenatal screening may not be available 
in developing countries, patients may present in later infancy. We pre-
sent successful surgical repair of a 6-month-old infant with TAPVR 
who presented for medical care at 5 months of age in Lima, Peru. The 
late presentation of such infants and the limited resources available 
for the treatment of elevated pulmonary vascular resistance may im-
pact successful surgical correction of such defects. The perioperative 
care of such infants in developing countries is discussed and strate-
gies for managing postoperative pulmonary hypertension is reviewed.
Keywords: Total anomalous pulmonary venous return; Congenital 
heart disease; Pulmonary hypertension
Introduction
Total anomalous pulmonary venous return (TAPVR) is a rare 
congenital cardiac defect, accounting for 1.5-3% of cases of 
congenital heart disease (CHD) [1, 2]. TAPVR results from 
failure of the formation of a common pulmonary vein from 
the left atrium with persistent connection of the primitive 
pulmonary vascular plexus to the common cardinal and um-
bilico-vitelline veins [3, 4]. TAPVR can be classified based 
on the anatomic defect (level of pulmonary venous drainage) 
or physiologic effect. Anatomic variants include supracardiac 
(40-50%), intracardiac (15-20%), infracardiac (25-30%) or 
mixed type (5-10%) while physiologic consequences include 
obstructive or non-obstructive venous drainage [3, 4]. Ob-
struction, which results in severe derangements immediately 
after birth, is usually due to the external compression from sur-
rounding structures or reduced caliber of the internal lumen 
due to pulmonary vein hypoplasia or stenosis [5]. Identifying 
the drainage sites and level of obstruction is important for de-
termining the surgical approach. Diagnosis is usually achieved 
by echocardiography and cardiac catheterization [6]. With the 
advent of improved prenatal ultrasonography, the majority of 
patients are diagnosed in utero. Although prenatal screening 
with ultrasonography and postnatal neonatal screening with 
pulse oximetry is generally effective in identifying the defect; 
such screening may not be available or routine in developing 
countries [7, 8].
If not identified during the newborn period with such 
screening, the age at which patients become clinically symp-
tomatic and present to the hospital depends on the presence or 
absence of obstruction and the existence of intra-cardiac or ex-
Manuscript submitted December 14, 2017, accepted January 4, 2018
aDepartment of Pediatrics, Children’s Hospital of New Jersey, Newark, NJ, 
USA
bHeart Care International, Greenwich, CT, USA
cDepartment of Pediatrics, Washington University, St. Louis, MO, USA
dDivision of Pediatric Critical Care, St. Louis Children’s Hospital, St. Louis, 
MO, USA
eDepartment of Anesthesiology and Pain Medicine, Nationwide Children’s 
Hospital, Columbus, OH, USA
fDepartment of Anesthesiology and Pain Medicine, The Ohio State University 
College of Medicine, Columbus, OH, USA
gDepartment of Cardiothoracic Surgery, el Instituto Nacional de Salud del 
Nino, Lima, Peru
hDepartment of Surgery, University of Nebraska, Omaha, NE, USA
iDivision of Cardiothoracic Surgery, University of Nebraska, Omaha, NE, 
USA
jDepartment of Pediatrics, University of Louisville, Louisville, KY, USA
kDivision of Pediatric Critical Care Medicine, University of Louisville, Lou-
isville, KY, USA
lDepartments of Anesthesiology and Pediatrics, Columbia University, New 
York, NY, USA
mDepartment of Cardiothoracic and Vascular Surgery, Montefiore Medical 
Center and Albert Einstein College of Medicine, New York, NY, USA
nCorresponding Author: Lakshmi R. Gokanapudy, Department of Pediatric 
Cardiology, Washington University School of Medicine, Saint Louis Chil-
dren’s Hospital, 1 Children’s Place, NWT Box 8116, St. Louis, MO 63110, 
USA. Email: Gokanapudy.L@wustl.edu
doi: https://doi.org/10.14740/cr651w
Articles © The authors   |   Journal compilation © Cardiol Res and Elmer Press Inc™   |   www.cardiologyres.org54
TAPVR in a Developing Country Cardiol Res. 2018;9(1):53-58
tra-cardiac shunts [9]. Clinical symptoms of congestive heart 
failure or hypoxemia, will not manifest until physiologic de-
rangements occur related to obstruction of pulmonary venous 
return or the large left-to-right shunt. We report a 6-month-old 
infant with supracardiac TAPVR that presented in a develop-
ing country (Peru) at 5 months of age with the primary clinical 
symptoms of tachypnea and poor feeding. The late presentation 
of such infants is discussed and the perioperative challenges 
reviewed with emphasis on the prevention and treatment of el-
evated pulmonary vascular resistance in a developing country.
Case Report
The patient in this report was cared for during a cardiac sur-
gery trip of Heart Care International (HCI) to El Instituto Na-
cional de Salud del Nino in Lima, Peru. HCI is a not-for-profit 
501(c)(3) foundation based in Greenwich, Connecticut that has 
provided pediatric cardiology and cardiac surgery services in 
developing countries since 1994. HCI’s goal is to not only pro-
vide primary cardiac surgical care, but also to train and educate 
host country health professionals. The majority of the equip-
ment and supplies necessary for these surgical procedures is 
shipped into the country by HCI. Informed consent for surgery 
was obtained from the family and the HCI Board of Directors 
approved this report.
A 6-month-old, 5.5 kg former full-term male infant, who 
had been thriving and breastfeeding without difficulty, first 
presented for medical care at 5 months of age with new on-
set tachypnea and wheezing. During hospitalization for sus-
pected pneumonia, a transthoracic echocardiogram was per-
formed and revealed supracardiac TAPVR to an unobstructed 
confluence superior to the left atrium with a large atrial septal 
defect (ASD). In Peru, this cardiac lesion carries a very high 
mortality and rarely will children receive the option for surgi-
cal correction. This patient was scheduled for surgical repair 
as part of Heart Care International’s twice annual pediatric 
cardiac surgical trip to Lima, Peru. On the day of surgery, a 
peripheral intravenous cannula (PIV) was placed to provide 
maintenance intravenous fluids and the patient was held nil per 
os for 6 h. He was transported to the operating room where 
routine American Society of Anesthesiologists’ monitors were 
placed. Anesthesia was induced with fentanyl (5 µg/kg) and 
ketamine (1 mg/kg) and neuromuscular blockade provided 
by rocuronium (1 mg/kg). Following anesthetic induction, a 
nasogastric tube was inserted and sildenafil (2 mg/kg) was 
administered. Maintenance anesthesia included sevoflurane 
(inspired concentration of 1-3%) and fentanyl (total dose of 
50 µg/kg). Endotracheal intubation was performed with a 3.5 
mm cuffed endotracheal tube. A second PIV, a left radial arte-
rial cannula, and a double lumen central venous catheter (in-
ternal jugular) were placed. Repair of the TAPVR was per-
formed using the previously reported “closed-vein” technique 
for primary sutureless repair [10]. Cannulation of the aorta, 
superior vena cava (SVC), and inferior vena cava (IVC) was 
performed along with placement of a vent in the vertical vein. 
The systemic temperature was maintained between 28 - 32 
°C. The venous confluence was exposed through the retracted 
ASD. The left atrial cuff was then sutured around the pulmo-
nary confluence. Once this was complete, the confluence was 
opened and all four pulmonary venous orifices were identified. 
The vertical vein was ligated and the ASD was closed with an 
autologous pericardial patch. Prior to weaning from cardiopul-
monary bypass (CPB), a loading dose of milrinone (25 µg/kg) 
was administered and an infusion started at 0.5 µg/kg/min. To 
maintain mean arterial pressure, an epinephrine infusion was 
initiated at 0.03 µg/kg/min. The patient was weaned from CPB 
without difficulty and heparin anticoagulation was reversed 
with protamine. Following weaning from CPB, mild hyper-
ventilation (PaCO2 30-35 mm Hg) was maintained with an in-
spired oxygen concentration ≥ 0.6. The total CPB time was 99 
min and aortic cross clamp time was 62 min. The patient was 
transported to the intensive care unit (ICU) with the endotra-
cheal tube in place, receiving mechanical ventilation. Ongo-
ing sedation was provided by continuous infusions of fentanyl 
and midazolam. The epinephrine infusion was discontinued on 
postoperative day (POD) 1 and the milrinone discontinued on 
POD 2. The patient’s trachea was extubated on POD 2 and the 
inspired oxygen concentration weaned to room air on POD 5. 
An echocardiogram on POD 1 revealed no obstruction to flow, 
no gradients across the pulmonary veins, and good myocardial 
function. Sildenafil was continued via the NG tube every 6 h 
for 7 days. The patient was eating well without complications 
and was discharged home on POD 7.
Discussion
TAPVR typically presents in infancy with the clinical signs 
and symptoms dependent on the site of drainage of the pulmo-
nary veins and the degree of obstruction. Infracardiac TAPVR, 
in which the pulmonary venous plexus drains into the sinus 
venosus below the diaphragm, almost always presents with an 
obstructed picture as the sinus venosus constricts shortly after 
birth. If not identified by routine ultrasonography during preg-
nancy or post-natal pulse oximetry screening, the supracardiac 
and intracardiac unobstructed variants of TAPVR can present 
later in life, manifesting symptoms related to the large left-to-
right shunt with volume overload [11].
Infants with obstructed TAPVR appear critically ill, pre-
senting at birth with marked cyanosis, tachypnea, dyspnea, 
hypoxemia, and metabolic acidosis. These children require 
urgent surgical repair [12]. In comparison, infants without ob-
struction, as was the case with our patient, may present later 
in infancy with signs and symptoms of congestive heart failure 
(tachypnea, poor feeding) related to volume overload and pul-
monary over-circulation. Alternatively, signs and symptoms of 
pulmonary hypertension (PH) may develop if the pulmonary 
venous return becomes obstructed. The relatively late presen-
tation of our patient at 5 months of life can be attributed to 
an unobstructed supracardiac TAPVR with a large unrestricted 
ASD allowing ample mixing at the atrial level and unimpeded 
pulmonary venous return.
When infants present later in life, several factors may 
complicate the perioperative care including ongoing failure to 
thrive, congestive heart failure, respiratory insufficiency, and 
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the potential for elevated pulmonary vascular resistance dur-
ing the perioperative period especially following CPB when 
endothelial cell dysfunction may be present. The surgical tech-
nique used in our patient (“suture-less technique”) is advan-
tageous as it avoids the need for profound hypothermia and 
circulatory arrest with the potential for neurologic damage, 
limits postoperative bleeding, and has a decreased incidence 
of late restenosis which are particularly beneficial in a resource 
poor setting. Postoperatively, these patients are at a significant 
clinical risk for increased pulmonary vascular resistance and 
pulmonary hypertensive crisis [13, 14]. Given the vasoreactive 
effects of alveolar oxygen and arterial carbon dioxide (PaCO2) 
on the pulmonary vasculature, simple maneuvers include mild 
hyperventilation and the delivery of a high inspired concentra-
tion of oxygen. Other perioperative factors that may increase 
pulmonary vascular resistance include acidosis, hypothermia, 
and the surgical stress response.
Medications that decrease systemic pressure by direct 
negative inotropic effects or systemic vasodilatation should be 
avoided as the precipitous decrease in systemic vascular re-
sistance may result in rapid decompensation and perioperative 
cardiac arrest. The importance of such issues are exemplified 
by the increased incidence of perioperative cardiac arrest in 
infants with CHD especially those with PH [13-15]. Intense 
analgesia with the use of a high-dose opioid technique with 
synthetic opioids (fentanyl or sufentanil) effectively controls 
the hyper adrenergic stress response and may effectively blunt 
pulmonary vascular reactivity [16]. In order to maintain sys-
temic pressure and avoid hypotension, anesthesia was induced 
with ketamine. Although previously postulated to be contrain-
dicated in the setting of PH, recent data has demonstrated keta-
mine to be a safe and effective agent in this patient population 
as it maintains or increases systemic vascular resistance with 
little effect on PVR [17, 18]. A high-dose opioid technique 
with fentanyl was used intraoperatively with postoperative 
mechanical ventilation to optimize oxygenation and ventila-
tion. Additionally, a postoperative fentanyl infusion was used 
to ensure adequate analgesia and sedation during the postop-
erative period during endotracheal intubation and mechanical 
ventilation.
Preexisting PH complicates the postoperative course in 
2-7% of patients undergoing surgery for CHD [19-21]. Many 
of the episodes of PH can be effectively prevented by simple 
maneuvers of avoiding hypothermia, hypoxemia, acidosis, 
and agitation. Respiratory management plays a critical role 
in the management of PH. It is crucial to maintain adequate 
lung volumes and gas exchange while avoiding acidosis in 
the postoperative period when pulmonary edema, atelectasis, 
ventilation-perfusion mismatch, and bronchoconstriction may 
increase pulmonary vascular resistance (PVR). The mainte-
nance of functional residual capacity (FRC) at baseline is cru-
cial as either atelectasis or over-distention of alveoli can in-
crease PVR. As such, positive end expiratory pressure should 
be titrated to maintain FRC. In our patient, sedation and ongo-
ing ventilation were continued into the postoperative period 
to allow for the provision of intense analgesia and effective 
control of oxygenation and ventilation. PH may be exacer-
bated by airway instrumentation including tracheal suction-
ing [16, 22]. A rapid increase in PVR can lead to right heart 
failure with a decrease in right ventricular ejection and failure. 
In the absence of a patent foramen ovale or atrial septostomy, 
right heart failure leads to a decrease in pulmonary blood 
flow, decreased pulmonary venous return to the left atrium, 
decreased cardiac output, and cardiac arrest. Treatment strate-
gies for PHC include the administration of 100% oxygen and 
hyperventilion to correct acidosis and provide a moderate de-
gree of hypocarbia (PaCO2 25 - 30 mm Hg) [23]. Once the 
PaCO2 is controlled, acidosis can be treated with the admin-
istration of sodium bicarbonate. Supplemental anesthesia can 
be administered especially if the crisis was precipitated by a 
noxious stimulus [24]. Cardiac output should be supported by 
the administration of fluid to increase preload and the use of 
inotropic agents as needed. Finally, various pharmacologic 
agents have been used for the treatment of PH including nitric 
oxide, phosphodiesterase inhibitors, prostacyclin analogues, 
and endothelin antagonists (Table 1) [25].
The time-honored and most commonly used pharmaco-
logic therapy to treat or prevent postoperative PH following 
surgery for CHD remains inhaled nitric oxide (iNO) [26-
28]. However, this agent may be not available in developing 
countries. NO is administered via inhalation, thereby limit-
ing its systemic effects and preventing decreases in systemic 
arterial pressure. NO increases intracellular cyclic guanosine 
monophosphate (cGMP) causing smooth muscle relaxation 
and vasodilation. NO binds to hemoglobin and is inactivated. 
Because it is a selective pulmonary vasodilator, easy to admin-
ister, and has a rapid onset, inhaled NO has become the pri-
mary therapy for postoperative PH. Once formed, intracellu-
lar cGMP is metabolized by phosphodiesterase type 5 (PDE). 
PDE type 5 inhibitors increase cGMP levels by preventing 
their breakdown, leading to vasodilatory effects on the pul-
monary vasculature. However, these medications are generally 
administered via the oral or intravenous route and hence also 
have significant effects on the systemic circulation. Sildenafil, 
the main PDE type 5 inhibitor can be administered via the oral 
or intravenous route [29-31]. Oral sildenafil has been shown 
to attenuate rebound PH after iNO withdrawal and shorten 
the time to extubation and the length of time that intensive 
care is needed [29]. More recently, an intravenous prepara-
tion has been introduced into clinical practice and shown to 
effectively control PH following surgery for CHD [31]. Al-
though currently approved for use in adults with PH, sildenafil 
is used extensively off-label for the treatment of neonates, in-
fants, and children with PH and may be used pre-emptively to 
mitigate pulmonary hypertensive crisis post-operatively as we 
attempted in this case. Despite such information, the United 
States Food and Drug Administration has recently cautioned 
against the long-term use of sildenafil in pediatric patients with 
PH due to an apparent increase in mortality during long-term 
therapy [32].
In an attempt to maximize pulmonary vasodilatation in 
this patient and to prevent PH, we used a combination of in-
travenous milrinone and enteral sildenafil. While both agents 
may impact systemic blood pressure, their vasodilatory effects 
on the pulmonary vasculature generally outweigh their sys-
temic effects [33]. In the event of a decrease in systemic blood 
pressure, inotropic support may be required and vasopressin 
is considered the agent of choice to increase systemic blood 
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pressure. In a preliminary study of 15 pediatric patients with 
PH, the ratio of pulmonary-to-systemic vascular resistance de-
creased in three of five patients receiving phenylephrine, five 
of five patients receiving arginine vasopressin, and three of 
five patients receiving epinephrine [34]. In an effort to avoid 
the potential systemic effects of milrinone, investigational 
studies have reported its administration via aerosol, offering an 
alternative agent in settings where NO is unavailable [35, 36].
Prostaglandin I2 (PGI2) or prostacylin has recently seen in-
creased use in the treatment of PH. PGI2 stimulates the cAMP 
pathway to increase pulmonary vasodilation. These agents are 
available for systemic or inhalational administration. Children 
with PH show diminished PGI2 synthase expression in lung 
vasculature, thus intravenous PGI2 has become one of the 
standards of treatment of severe PH with right heart failure, 
showing improvements in long-term survival and quality of 
life. However, the intravenous route is generally used only for 
long-term therapy and not in the acute treatment or prevention 
of a PH crisis during the perioperative period. Although these 
agents have been shown to improve survival, their long-term 
administration may be cumbersome. Epoprostenol (Flolan®) 
requires continuous infusion without interruption via a central 
line, given its half life of 5 - 6 min. Treprostinil (Remodulin®) 
has a longer half-life (4 h) and is administered by continuous 
subcutaneous administration. The inhaled PGI2 analog, ilo-
prost (Ventavis®), on the other hand is administered as a nebu-
lization at 3 - 4 h intervals, and has the advantage of causing 
selective pulmonary vasodilation without affecting systemic 
blood pressure [37-39]. Given their rapid responsiveness and 
limited systemic effects, these agents may have a role in the 
treatment of an acute PH crisis. Endothelin 1 is a potent vaso-
constrictor with several receptor subtypes on vascular smooth 
muscle. Bosentan is the main endothelin receptor antagonist 
in use; however, other agents that provide more selective re-
ceptor antagonism have recently been introduced for clinical 
care [40]. Bosentan is administered orally, lowers pulmonary 
vascular resistance, and improves exercise tolerance with 
long-term administration. However, our experience has dem-
onstrated that these agents (prostaglandin analogues and en-
dothelin antagonists) are generally not available in developing 
countries.
In summary, we offer a potential clinical pathway for the 
management of TAPVR in developing countries where re-
sources may be limited. In developing countries and in partic-
ular, on medical missions, the standard pharmacologic agents 
(nitric oxide, prostaglandin analogues, and bosentan) may not 
be available. In general, pharmacologic therapy of PH is lim-
ited to enteral sildenafil (PR or NG), intravenous milrinone, 
and intravenous vasopressin. Pre-trip planning must include 
consideration of agents and techniques to treat PH taking into 
account cost, ease of transport, long-term therapy, experience 
of the host country healthcare team, and specific customs regu-
lations which may impact on drug availability. Given the late 
presentation our patient, perioperative care was compounded 
Table 1.  Management of Perioperative Pulmonary Hypertensive Crisis
1. Correct hypoxemia and hypercarbia
2. Administer 100% oxygen
3. Hyperventilation
4. Maintain normothermia
5. Alkalization with the administration of sodium bicarbonate
6. Treat noxious stimuli by deepening the level of anesthesia or administering opioids such as fentanyl
7. After sedation and analgesia, provide neuromuscular blockade
8. Support cardiac output by administering fluid or inotropic agents
  Vasopressin is preferable to adrenergic agents to increase mean arterial pressure without raising pulmonary artery pressure
9. Pharmacologic therapies
  Nitric oxide
  Increase intracellular cyclic GMP by inhibiting phosphodiesterase 5
    Milrinone
    Sildenafil (PR or NG)
  Augment prostaglandin G2 (prostacyclin) system (systemic or inhaled)
    Epoprostenol (Flolan®)
    Treprostinil (Remodulin®)
  Inhibit endothelin system
    Bosentan
  Miscellaneous agents
    Nesiritide
    levosimendan
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by comorbid features of failure to thrive, chronic congestive 
heart failure from volume overload, and the potential for post-
operative PH. Unfortunately, the majority of similar patients 
will die in the absence of the availability of appropriate medi-
cal management for PH and surgical expertise to treat the le-
sion. While it was fortuitous that Heart Care International was 
in the country at the time of presentation of this infant, the 
management of these patients is difficult in any country. Man-
agement of these patients is particularly difficult with limited 
pharmacologic agents and especially with the scarcity of ad-
vanced pharmacotherapies such as inhaled nitric oxide (Table 
1). A thorough understanding of cardiopulmonary physiology 
including respiratory mechanics, acid-base interactions, pul-
monary vascular reactivity, and cardiovascular physiology by 
a multidisciplinary team (cardiothoracic surgeons, intensivists, 
anesthesiologists, and cardiologists) will optimize patient out-
comes and can be shared with colleagues in developing coun-
tries [41-44].
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